Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 18/20 | 0.47 |
| ▸ | PLA2G1B | P04054 | 7/20 | 0.43 |
| ▸ | PLA2G10 | O15496 | 3/20 | 0.43 |
| ▸ | PLA2G5 | P39877 | 3/20 | 0.43 |
| ▸ | PLA2G2E | Q9NZK7 | 2/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.39 |
| ▸ | PLA2G6 | O60733 | 1/20 | 0.39 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.39 |
| ▸ | PLA2G12B | Q9BX93 | 1/20 | 0.39 |
| ▸ | PLA2G12A | Q9BZM1 | 1/20 | 0.39 |
| ▸ | PLA2G2F | Q9BZM2 | 1/20 | 0.39 |
| ▸ | PLA2G3 | Q9NZ20 | 1/20 | 0.39 |
| ▸ | PLA2G2D | Q9UNK4 | 1/20 | 0.39 |
| ▸ | TSPO | P30536 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5514622 | 0.94 | PLA2G2A (0.49) | PLA2G2APLA2G1BPLA2G10PLA2G5PLA2G2E | |
| SCHEMBL5864614 | 0.93 | PLA2G2A (0.47) | PLA2G2APLA2G1BPLA2G10PLA2G5PLA2G2E | |
| SCHEMBL6659796 | 0.92 | PLA2G2A (0.42) | PLA2G2APLA2G1BPLA2G10PLA2G5TSPO | |
| SCHEMBL5864640 | 0.91 | PLA2G2A (0.58) | PLA2G2APLA2G1BPLA2G10PLA2G5PLA2G2E | |
| SCHEMBL5864549 | 0.89 | PLA2G2A (0.51) | PLA2G2APLA2G1BPLA2G10PLA2G5PLA2G2E | |
| SCHEMBL5864524 | 0.88 | PLA2G2A (0.49) | PLA2G2APLA2G1BPLA2G10PLA2G5PLA2G2E | |
| SCHEMBL5864635 | 0.88 | PLA2G2A (0.51) | PLA2G2APLA2G1BPLA2G10PLA2G5PLA2G2E | |
| SCHEMBL5864665 | 0.88 | PLA2G2A (0.51) | PLA2G2APLA2G1BPLA2G10PLA2G5PLA2G2E | |
| SCHEMBL5864642 | 0.87 | PLA2G2A (0.47) | PLA2G2APLA2G1BPLA2G10PLA2G5PLA2G2E | |
| SCHEMBL5505593 | 0.87 | PLA2G2A (0.49) | PLA2G2APLA2G1BPLA2G10PLA2G5PLA2G2E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7109231-B2 | Cyclohept[b]indole derivatives | ELI LILLY AND COMPANY (US) | 2006-09-19 | — | — | US | claimed |
| EP-1438290-B1 | CYCLOHEPT B!INDOLE DERIVATIVES AS SPLA2 INHIBITORS | LILLY CO ELI (US) | 2005-12-14 | — | — | EP | claimed |
| US-20040198801-A1 | Cyclohept'b!indole derivatives as spla2 inhibitors | KINNICK MICHAEL DEAN (US) | 2004-10-07 | — | — | US | claimed |
| US-7109231-B2 | Cyclohept[b]indole derivatives | ELI LILLY AND COMPANY (US) | 2006-09-19 | — | — | US | disclosed |
| EP-1438290-B1 | CYCLOHEPT B!INDOLE DERIVATIVES AS SPLA2 INHIBITORS | LILLY CO ELI (US) | 2005-12-14 | — | — | EP | disclosed |
| US-20040198801-A1 | Cyclohept'b!indole derivatives as spla2 inhibitors | KINNICK MICHAEL DEAN (US) | 2004-10-07 | — | — | US | disclosed |
| EP-1438290-A1 | CYCLOHEPT B!INDOLE DERIVATIVES AS SPLA2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2004-07-21 | — | — | EP | disclosed |
| WO-2003016277-A1 | CYCLOHEPT`B!INDOLE DERIVATIVES AS SPLA2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2003-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198801-A1 | Cyclohept'b!indole derivatives as spla2 inhibitors | SPTSSB, CPT1A, TPH2 | PLA2G2A 82/4885PLA2G1B 47/4885PLA2G10 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.